RUGGIERO, ANGELO
 Distribuzione geografica
Continente #
NA - Nord America 1.408
EU - Europa 673
AS - Asia 489
AF - Africa 42
SA - Sud America 4
Continente sconosciuto - Info sul continente non disponibili 1
Totale 2.617
Nazione #
US - Stati Uniti d'America 1.402
SG - Singapore 375
IT - Italia 308
DE - Germania 146
NL - Olanda 71
CN - Cina 48
CI - Costa d'Avorio 35
IN - India 32
FI - Finlandia 31
GB - Regno Unito 26
IE - Irlanda 21
SE - Svezia 15
JP - Giappone 14
UA - Ucraina 14
BG - Bulgaria 10
CA - Canada 5
FR - Francia 5
PK - Pakistan 5
PL - Polonia 4
RS - Serbia 4
BE - Belgio 3
HK - Hong Kong 3
PT - Portogallo 3
BO - Bolivia 2
CZ - Repubblica Ceca 2
DZ - Algeria 2
EE - Estonia 2
EG - Egitto 2
ES - Italia 2
MK - Macedonia 2
MY - Malesia 2
AE - Emirati Arabi Uniti 1
AM - Armenia 1
AR - Argentina 1
BR - Brasile 1
CY - Cipro 1
EU - Europa 1
GL - Groenlandia 1
GR - Grecia 1
HR - Croazia 1
HU - Ungheria 1
IL - Israele 1
KG - Kirghizistan 1
KR - Corea 1
MA - Marocco 1
RU - Federazione Russa 1
SA - Arabia Saudita 1
TN - Tunisia 1
TR - Turchia 1
UZ - Uzbekistan 1
VN - Vietnam 1
ZA - Sudafrica 1
Totale 2.617
Città #
Singapore 306
Santa Clara 247
Chandler 191
Ashburn 124
Amsterdam 69
Lawrence 55
Boston 43
Millbury 43
Napoli 40
Naples 38
Des Moines 34
Milan 28
Rome 28
Krefeld 23
Lappeenranta 19
Seattle 18
Houston 16
Wilmington 15
Dublin 14
Woodbridge 14
Fairfield 12
Washington 12
Los Angeles 11
Helsinki 10
Pune 10
Sofia 10
Turin 10
Kronberg 9
Menlo Park 9
Arezzo 8
Cagliari 8
Council Bluffs 7
Karlsruhe 7
Magenta 7
Florence 6
Freiburg im Breisgau 6
Fremont 6
Guangzhou 6
Tokyo 6
Catania 5
Edinburgh 5
Munich 5
Okazaki 5
Afragola 4
Boardman 4
Esslingen am Neckar 4
Kochi 4
Mountain View 4
Redwood City 4
Xi'an 4
Zhengzhou 4
Avella 3
Brussels 3
Dallas 3
Frankfurt am Main 3
Islamabad 3
Mumbai 3
Nanjing 3
Rio Tinto 3
Roccasecca 3
Rottweil 3
Santa Maria La Carita 3
Shenzhen 3
Warsaw 3
Bergamo 2
Bhundsi 2
Bisceglie 2
Bologna 2
Cairo 2
Carugate 2
Castellammare di Stabia 2
Chengdu 2
Cologne 2
Corteolona 2
Espoo 2
Giugliano in Campania 2
Glasgow 2
Golasecca 2
Imola 2
Kerken 2
La Paz 2
Macerata 2
Modena 2
Norwalk 2
Nuremberg 2
Orta Nova 2
Palermo 2
Perugia 2
Piano di Conca 2
Putrajaya 2
Quartu Sant'elena 2
Redmond 2
San Diego 2
Sarno 2
Schoenwalde 2
Selargius 2
Sialkot 2
Streatham 2
Tallinn 2
Toenisvorst 2
Totale 1.688
Nome #
Review of oral minoxidil as treatment of hair disorders: in search of the perfect dose 133
Drug safety evaluation of tildrakizumab for psoriasis: a review of the current knowledge 64
Guselkumab, Risankizumab, and Tildrakizumab in the Management of Psoriasis: A Review of the Real-World Evidence 51
Biologics for psoriasis patients in the COVID-19 era: more evidence, less fears 51
Efficacy and safety of risankizumab in psoriasis patients who failed anti‐IL‐17, anti‐12/23 and/or anti IL‐23: preliminary data of a real‐life 16‐week retrospective study 51
Eczematous drug eruption in patients with psoriasis under anti‐interleukin‐17A: does interleukin‐22 play a key role? 42
The efficacy and safety of abrocitinib as a treatment option for atopic dermatitis: A short report of the clinical data 39
Anti‐interleukin‐23 for psoriasis in elderly: guselkumab, risankizumab and tildrakizumab in real world practice 39
Giant nodular melanoma of the nose in a 78‐year old female refusing complete excision 38
QuantiFERON TB‐gold conversion rate among psoriasis patients under biologics: a 9‐year retrospective study 38
Low dose oral corticosteroids, microneedling, and topical 5-fluorouracil: A novel treatment for recalcitrant pediatric vitiligo 37
Impact of current anti-psoriatic systemic treatments on male and female fertility: what the endocrinologist needs to know 34
Teledermatology for acne during COVID-19: high patients' satisfaction in spite of the emergency 32
Risankizumab in real life: preliminary results of efficacy and safety in psoriasis during a 16-week period 32
Bimekizumab for the Treatment of Psoriasis: A Review of the Current Knowledge 32
New frontiers in personalized medicine in psoriasis 30
Risankizumab treatment in psoriasis patients who failed anti-IL17: a 52-week real-life study 29
Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part II: focus on elderly patients 28
Guselkumab in moderate to severe psoriasis in routine clinical care: an Italian 44-week real-life experience 28
Ixekizumab: an efficacious treatment for both psoriasis and hidradenitis suppurativa 28
A case of erythrodermic psoriasis successfully treated with guselkumab 28
Effectiveness of Brodalumab in Patients with Moderate-to-Severe Plaque Psoriasis Located in Difficult-to-Treat Areas 27
The impact of COVID ‐19 infection on psoriatic patients treated with biologics: an Italian experience 27
A case of severe psoriasis in a 84-year old women successfully treated with ixekizumab 27
Secukinumab during pregnancy: a case report and review of literature 27
Guselkumab is efficacious and safe in psoriasis patients who failed anti-IL17: a 52-week real-life study 27
An atypical ear nodule 27
A case of linear psoriasis in a young patient with Down syndrome and review of the literature 26
Ixekizumab and brodalumab indirect comparison in the treatment of moderate to severe psoriasis: results from an Italian single-centre retrospective study in a real-life setting 26
Cutaneous involvement during COVID-19 pandemic: an emerging sign of infection 26
Reply to "Where are the older adults? Age distribution of nail psoriasis-randomized clinical trials' participants: a systematic review" by Ricardo JW et al 25
Biologics for patients affected by Hidradenitis suppurativa in the COVID-19 era: data from a referral centre of Southern Italy 25
A case of esophageal candidiasis in a psoriatic patient treated with ixekizumab: should treatment be discontinued? 25
The Role of Teledermatology During the COVID-19 Pandemic: A Narrative Review 24
Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part I: focus on pediatric patients 24
A case of erythrodermic psoriasis rapidly and successfully treated with Bimekizumab 24
Teledermatology and chronic skin diseases: real life experience in a Southern Italian Dermatologic Centre 24
New emergent therapies for atopic dermatitis: A review of safety profile with respect to female fertility, pregnancy, and breastfeeding 24
Paradoxical Hidradenitis Suppurativa during Biologic Therapy, an Emerging Challenge: A Systematic Review 24
May COVID-19 outbreaks lead to a worsening of skin chronic inflammatory conditions? 23
Efficacy and safety of guselkumab in psoriasis patients who failed ustekinumab and/or anti IL-17: a real-life 52-week retrospective study 23
Wound care, adalimumab, and multidisciplinary approach in a patient affected by PASH syndrome 23
A case of erythrodermic psoriasis successfully treated with apremilast 23
The Impact of COVID-19 Vaccination on Inflammatory Skin Disorders and Other Cutaneous Diseases: A Review of the Published Literature 22
Persistent candidiasis infection during anti‐ IL ‐17 treatment for plaque psoriasis requiring biologic discontinuation: a case series and literature review 22
Dupilumab associated inflammatory arthritis: a literature review 22
Skin Needling in Combination with Antimicrobial Peptides for the Treatment of Keloids: A Novel Perspective Proposal and Approach for Skin Scars 22
Secukinumab: a potential safe option in psoriasis patients affected by multiple sclerosis? 22
A Case of Ofuji Disease Successfully Treated with the Combination of Low-Dose Indomethacin and Topical Tacrolimus 22
Chronic cutaneous ulcers management in dermatologic department during COVID-19 era 22
Real-world practice indirect comparison between guselkumab, risankizumab and tildrakizumab: results from an Italian 28-week retrospective study 22
Reply to ‘Impact of the French COVID ‐19 pandemic lockdown on newly diagnosed melanoma delay and severity’ by R. Molinier et al 21
Tildrakizumab for the treatment of moderate to severe psoriasis: results from a single center preliminary real‐life study 21
Community Knowledge About the Use, Reuse, Disinfection and Disposal of Masks and Filtering Facepiece Respirators: Results of a Study Conducted in a Dermatology Clinic at the University of Naples in Italy 21
Anti-IL23 biologic therapies in the treatment of psoriasis: real-world experience versus clinical trials data 20
Injections Site Reactions and Biologics for Psoriasis: A Questionnaire Based Real Life Study 20
Hidradenitis Suppurativa in a Patient Affected by Mayer-Rokitansky-Küster-Hauser Syndrome: Insight into the Role of Hormones in HS 20
Dose reduction during routine treatment of locally advanced basal cell carcinoma with the hedgehog inhibitor sonidegib to manage adverse effects: A retrospective case series 20
Patient satisfaction with remote dermatology consultations during the COVID-19 pandemic. Comment on 'A qualitative assessment of patient satisfaction with remote dermatology consultations used during the UK's first wave of the COVID-19 pandemic in a single, secondary-care dermatology department' 19
Reply to 'Cutaneous adverse effects of the available COVID-19 vaccines in India: A questionnaire-based study' by Bawane J et al 19
Long-Term Efficacy and Safety of Guselkumab for Moderate to Severe Psoriasis: A 3-Year Real-Life Retrospective Study 19
A case of generalized granuloma annulare successfully treated by hydroxychloroquine 19
Ocular Manifestations in Psoriasis Screening (OcMaPS) Questionnaire: A Useful Tool to Reveal Misdiagnosed Ocular Involvement in Psoriasis 19
New-Onset Psoriatic Arthritis under Biologics in Psoriasis Patients: An Increasing Challenge? 19
Real world practice indirect comparison between guselkumab and risankizumab: results from an Italian retrospective study 19
Telemedicine and support groups could be used to improve adherence to treatment and health-related quality of life in patients affected by inflammatory skin conditions during the COVID-19 pandemic 19
Neoadjuvant use of methotrexate in eosinophilic angiocentric fibrosis of upper lip and hard palate: A case report 19
The Use of JAK/STAT Inhibitors in Chronic Inflammatory Disorders 19
Efficacy and safety of deucravacitinib for the management of psoriasis: a drug safety evaluation 18
Injection site reactions resulting from the use of biological therapy in the treatment of moderate-to-severe plaque psoriasis 18
Teledermatology in the management of hidradenitis suppurativa: Should we improve this service? 18
Long-Term Efficacy and Safety of Risankizumab for Moderate to Severe Psoriasis: A 2-Year Real-Life Retrospective Study 18
Author reply to: Comment on: 'Eczematous drug eruption in patients with psoriasis under anti-interleukin-17A: does interleukin-22 play a key role?' 18
QuantiFERON TB-gold conversion is not uncommon in psoriasis patients under anti-TNF-α 18
Face the COVID-19 emergency: measures applied in an Italian Dermatologic Clinic 18
Safety of dupilumab in atopic patients during COVID-19 outbreak 18
Reply to "Psoriasis exacerbation after Covid-19 vaccination: report of 14 cases from a single center" by Sotiriou E et al 18
New Onset and Exacerbation of Psoriasis Following COVID-19 Vaccination: A Review of the Current Knowledge 18
Bullous pemphigoid and COVID ‐19 vaccination: management and treatment Reply to ‘Bullous pemphigoid in a young male after COVID ‐19 mRNA vaccine: a report and brief literature review’ by Pauluzzi et al 17
Efficacy and Safety of bimekizumab in psoriasis management in real-life: bio-naïve vs bio-experienced 17
Guselkumab, Risankizumab, and Tildrakizumab in the Management of Hidradenitis Suppurativa: A Review of Existing Trials and Real-Life Data 17
The hidden sentinel of the skin: An overview on the role of interleukin-13 in atopic dermatitis 17
Reply to “Nail psoriasis: a rare mRNA COVID ‐19 vaccine reaction” by Lamberti A et al 17
Etanercept for pediatric acrodermatitis continua of Hallopeau: a case report and literature review 17
JAK Inhibitors in Psoriatic Disease 16
Cutaneous adverse reaction following COVID-19 vaccination: Report from a southern Italian referral centre. Comment on "cutaneous adverse reactions following the Pfizer/BioNTech COVID-19 vaccine" by Luo et al 16
Comment on: "Associations between hidradenitis suppurativa and dermatological conditions in adults: A national cross-sectional study by Brown et al." 16
Management of patients with hidradenitis suppurativa during COVID-19 vaccination: an experience from southern Italy. Comment on: 'Evaluating the safety and efficacy of COVID-19 vaccination in patients with hidradenitis suppurativa' 16
Hidradenitis Suppurativa and JAK Inhibitors: A Review of the Published Literature 15
Efficacy and Safety of Tildrakizumab in a Patient with Chronic HBV Infection 15
Advanced Squamous Cell Carcinoma Developed on Chronic Hidradenitis Suppurativa, Successfully Treated with Cemiplimab: A Case Report 15
Long-Term Efficacy and Safety of Guselkumab in Psoriasis Patients Who Failed Anti-IL17: A Two-Year Real-Life Study 15
Reply to "Routine re-screening for latent tuberculosis has low utility in patients with chronic immune-mediated inflammatory diseases treated with biologics: a single-center retrospective cohort study" 15
The impact of COVID-19 pandemic on nonmelanoma skin cancers: report of a Southern Italy referral centre 14
Comment on 'Morphoea following COVID-19 vaccination' 14
Strategies to Improve Outcomes of Bullous Pemphigoid: A Comprehensive Review of Clinical Presentations, Diagnosis, and Patients' Assessment 14
Development of a Patient-Reported Outcome Measure (PROM) for Dysgeusia During Treatment With Smoothened (SMO) Inhibitors for Basal Cell Carcinomas: The SMO-iD Questionnaire 13
Comment on: “Clinical characteristics of patients with pityriasis rubra pilaris following SARS‐CoV‐2 vaccination” by Gambichler 13
Towards Personalized Medicine in Psoriasis: Current Progress 13
A Case of Erythrodermic Psoriasis Successfully Treated with Risankizumab 13
Totale 2.459
Categoria #
all - tutte 18.193
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 18.193


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202036 0 0 0 0 0 0 0 1 2 11 4 18
2020/2021188 16 12 6 5 21 8 5 54 9 35 17 0
2021/2022322 2 2 3 13 22 23 2 20 4 44 45 142
2022/2023684 59 43 35 24 68 70 57 80 91 81 56 20
2023/2024755 32 97 83 67 42 70 21 74 23 27 133 86
2024/2025794 211 226 30 34 123 170 0 0 0 0 0 0
Totale 2.779